Could a common blood pressure pill boost radiation against tough pancreatic tumors?
NCT ID NCT04106856
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 3 times
Summary
This early-phase study tests whether adding losartan (a blood pressure medicine) to a shorter, higher-dose radiation treatment can help people with pancreatic cancer that is hard to remove surgically. The main goal is to check for side effects and find the safest dose. About 22 adults with borderline resectable or locally advanced pancreatic cancer will receive losartan alongside radiation after standard chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Four-Drug cocktail aims to shrink pancreatic tumors before surgery
- Could a Decades-Old parasite drug help fight pancreatic cancer?
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Triple threat against pancreatic cancer: radiation, immunotherapy, and chemotherapy combined
- Can a tailored web portal help pancreatic cancer patients exercise and eat better during chemotherapy?
- Experimental combo therapy targets Hard-to-Treat pancreatic cancer